Clinical Trials

Inclusion Criteria:

• Participants must have an index event that meets all 3 of the following criteria within 7 days prior to randomization:
  • clinical syndrome consistent with spontaneous cardiac ischemia;
  • diagnosis of acute coronary syndrome (ACS) (that is, ST-elevation myocardial infarction [STEMI], non-STEMI, or unstable angina [UA]);
  • cardiac biomarker elevation (example, troponin I, troponin T, creatine kinase-MB [CK-MB]) above the upper limit of normal as determined by the local laboratory.
• Participants must have at least 2 of the following risk factors:
  • age 65 or older;
  • diabetes mellitus;
  • history of a prior myocardial infarction (MI) (other than index ACS event);
  • multivessel coronary artery disease (CAD);
  • history of coronary artery bypass graft (CABG) surgery prior to index ACS event;
  • history of peripheral artery disease (PAD) or cerebrovascular disease (example, carotid atherosclerosis, intracranial artery stenosis;
  • conservative management (that is, no percutaneous intervention [PCI] or CABG after index ACS event).
• Any one or more of the following high-risk angiographic features:
  • total stent length of greater than (>) 30 millimeters (mm);
  • thrombotic target lesion;
  • bifurcation lesion treated with more than one stent;
  • calcified target lesion treated with atherectomy;
  • treatment of obstructive left main or proximal left anterior descending artery for index ACS (or clinical diagnosis of an anterior STEMI).
• All female participants of childbearing potential must have a negative highly sensitive serum beta-human chorionic gonadotropin (hCG) or urine test at screening.
• A female participant must not be pregnant, breastfeeding, or planning to become pregnant until 4 days (5 half-lives) after the last dose of study intervention.

Exclusion Criteria:

• MI secondary to ischemia due to either increased oxygen demand or decreased supply (Type 2 MI) or periprocedural MI as the index ACS event.
• Planned CABG or staged PCI after randomization.
• Any condition that requires chronic anticoagulation at the discretion of the investigator and/or local guidelines.
• Conditions with a significant increased risk of bleeding (i.e., clinically significant bleeding within previous 3 months, known bleeding diathesis, et. cetera).

Eligibility last updated 5/18/23. Questions regarding updates should be directed to the study team contact.